Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 3
1993 8
1994 1
1995 2
1996 6
1997 4
1998 5
1999 7
2000 4
2001 10
2002 6
2003 7
2004 3
2005 4
2006 9
2007 4
2008 8
2009 4
2010 6
2011 1
2012 1
2013 3
2014 6
2015 7
2016 5
2017 5
2018 5
2019 8
2020 6
2021 2
2022 4
2023 8
2024 8
2025 8
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T; CERTAIN-1 Study Team. Wagenlehner FM, et al. N Engl J Med. 2024 Feb 15;390(7):611-622. doi: 10.1056/NEJMoa2304748. N Engl J Med. 2024. PMID: 38354140 Clinical Trial.
Composite success occurred in 207 of 293 patients (70.6%) in the cefepime-taniborbactam group and in 83 of 143 patients (58.0%) in the meropenem group. Cefepime-taniborbactam was superior to meropenem regarding the primary outcome (treatment difference, 12.6 percent …
Composite success occurred in 207 of 293 patients (70.6%) in the cefepime-taniborbactam group and in 83 of 143 patients (58.0%) in th …
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, Velicitat P. Kaye KS, et al. JAMA. 2022 Oct 4;328(13):1304-1314. doi: 10.1001/jama.2022.17034. JAMA. 2022. PMID: 36194218 Free PMC article. Clinical Trial.
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections. ...A total of 1.7% (9/516) of participants who received cefepime/enmetazobactam and 0.8% (4/518) …
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for …
Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis.
Onorato L, de Luca I, Salvati A, Monari C, Coppola N. Onorato L, et al. Infection. 2025 Jun;53(3):1141-1153. doi: 10.1007/s15010-024-02447-y. Epub 2024 Dec 4. Infection. 2025. PMID: 39630396
OBJECTIVES: To describe the clinical and microbiological outcomes of patients treated with piperacillin/tazobactam, cefepime or carbapenems for bloodstream infections (BSIs) due to c-AmpC beta-lactamase-producing strains. ...No difference was observed in microbiological an …
OBJECTIVES: To describe the clinical and microbiological outcomes of patients treated with piperacillin/tazobactam, cefepime or carba …
Unveiling predisposing factors for cefepime-induced neurotoxicity: A systematic review and meta-analysis.
Hardi H, Louisa M, Widyahening IS, Chandra JR, Mahata LE, Soetikno V, Gayatri A, Instiaty I. Hardi H, et al. Br J Clin Pharmacol. 2025 Aug;91(8):2192-2204. doi: 10.1002/bcp.70120. Epub 2025 Jun 16. Br J Clin Pharmacol. 2025. PMID: 40523836
AIMS: The aim of this study was to elucidate the risk factors associated with the development of cefepime-induced neurotoxicity (CIN). METHODS: This systematic review utilized keywords "cefepime" and "neurotoxicity", sourced from PubMed, Scopus, Web of Science and G …
AIMS: The aim of this study was to elucidate the risk factors associated with the development of cefepime-induced neurotoxicity (CIN) …
Safety of cefepime: a new extended-spectrum parenteral cephalosporin.
Neu HC. Neu HC. Am J Med. 1996 Jun 24;100(6A):68S-75S. doi: 10.1016/s0002-9343(96)00110-6. Am J Med. 1996. PMID: 8678100 Free article.
Cefepime was compared with ceftazidime (1,456 patients), a third-generation cephalosporin. ...A limited number of cefepime-treated patients received 2 g every 8 hours. The median length of dosing for both cefepime and ceftazidime was 7 days. ...
Cefepime was compared with ceftazidime (1,456 patients), a third-generation cephalosporin. ...A limited number of cefepime-tre …
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Moeck G, Gasink LB, Mendes RE, Woosley LN, Dorr M, Chen H, Wagenlehner FM, Henkel T, McGovern PC. Moeck G, et al. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0023624. doi: 10.1128/aac.00236-24. Epub 2024 May 23. Antimicrob Agents Chemother. 2024. PMID: 38780262 Free PMC article. Clinical Trial.
We determined susceptibility of Enterobacterales and Pseudomonas aeruginosa baseline pathogens to cefepime-taniborbactam and comparators and characterized beta-lactam resistance mechanisms. ...Cefepime-taniborbactam demonstrated efficacy in adult cUTI patients with …
We determined susceptibility of Enterobacterales and Pseudomonas aeruginosa baseline pathogens to cefepime-taniborbactam and comparat …
Efficacy and safety of cefepime: a systematic review and meta-analysis.
Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Yahav D, et al. Lancet Infect Dis. 2007 May;7(5):338-48. doi: 10.1016/S1473-3099(07)70109-3. Lancet Infect Dis. 2007. PMID: 17448937
Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. ...This Review provides evidence and offers possible explanations for increased mortality among patients treated with cefepime in randomised trials... …
Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. ...This Review pr …
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Kong W, Deng T, Li S, Shu Y, Wu Y. Kong W, et al. BMC Infect Dis. 2023 Apr 21;23(1):256. doi: 10.1186/s12879-023-08209-9. BMC Infect Dis. 2023. PMID: 37085768 Free PMC article.
No statistically significant differences were found among antimicrobial agents regarding microbiological success rates. Cefepime plus metronidazole had lower risk of all-cause mortality than tigecycline (OR = 0.22, 95% CrI 0.05 ~ 0.85). ...CONCLUSION: This study suggests t …
No statistically significant differences were found among antimicrobial agents regarding microbiological success rates. Cefepime plus …
Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.
Asempa TE, Kuti JL, Nascimento JC, Pope SJ, Salerno EL, Troy PJ, Nicolau DP. Asempa TE, et al. J Antimicrob Chemother. 2023 Mar 2;78(3):703-709. doi: 10.1093/jac/dkac447. J Antimicrob Chemother. 2023. PMID: 36617636 Free PMC article. Clinical Trial.
INTRODUCTION: Taniborbactam (formerly VNRX-5133) is an investigational beta-lactamase inhibitor in clinical development in combination with cefepime for the treatment of MDR Gram-negative pathogens. OBJECTIVES: To assess the safety profile and pulmonary disposition of 2-0. …
INTRODUCTION: Taniborbactam (formerly VNRX-5133) is an investigational beta-lactamase inhibitor in clinical development in combination with …
Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR. Mustafa MM, et al. Pediatr Infect Dis J. 2001 Mar;20(3):362-9. doi: 10.1097/00006454-200103000-00036. Pediatr Infect Dis J. 2001. PMID: 11303851 Review.
RESULTS: Of 68 patients who could be evaluated for efficacy, 74% (26 of 35) of cefepime-treated patients and 70% (23 of 33) of ceftazidime-treated patients responded to treatment. ...In a modified intent-to-treat analysis, 59% of the patients treated with cefepime a …
RESULTS: Of 68 patients who could be evaluated for efficacy, 74% (26 of 35) of cefepime-treated patients and 70% (23 of 33) of ceftaz …
170 results